Braveheart Bio, Inc. (BRVE)
| Market Cap | 1.65B |
| Revenue (ttm) | n/a |
| Net Income | -98.46M |
| EPS | -14.68 |
| Shares Out | 81.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,617 |
| Open | 20.27 |
| Previous Close | 20.36 |
| Day's Range | 20.27 - 20.27 |
| 52-Week Range | 17.86 - 32.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.25 (+123.24%) |
| Est. Earnings | Nov 19, 2026 |
About BRVE
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BRVE stock is "Strong Buy." The 12-month stock price target is $45.25, which is an increase of 123.24% from the latest price.
News
Braveheart Bio Transcript: Stifel 2026 Virtual Cardiometabolic Forum
The forum highlighted strong clinical progress in HCM, with BHB-1893 showing rapid, deep efficacy and a differentiated safety profile. Simplified dosing, positive regulatory feedback, and robust financials position the program for global phase III advancement and potential early filing.
Braveheart Bio falls -13.9%
Braveheart Bio (BRVE) is down -13.9%, or -$4.06 to $25.14.
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopath...
Braveheart Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Lead asset BHB-1893 has shown promising phase II results in both obstructive and non-obstructive HCM, with significant biomarker and structural improvements. Global phase III trials are underway, aiming for simplified dosing and broader market adoption, supported by a robust regulatory and financial strategy.
Braveheart Bio Slides: Corporate presentation
Braveheart Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effe...
Braveheart Bio Earnings release: Q2 2026
Braveheart Bio released its Q2 2026 earnings on September 8, 2026, summarizing the period's financial results.
Braveheart Bio Quarterly report: Q2 2026
Braveheart Bio has published its Q2 2026 quarterly earnings report on September 8, 2026.
Braveheart Bio to Participate in Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopath...
Cantor starts Braveheart at Overweight on favorable setup into data
Cantor Fitzgerald initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target The firm sees “plenty to play for from here” despite the stock’s recent rally.
Braveheart Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target
Braveheart Bio initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Braveheart Bio (BRVE) with a Buy rating and no price target The company’s BHB-1893 has generated one of the most differentiated cardiac myosin inhibitor datasets…
Braveheart Bio initiated with a Buy at Jefferies
Jefferies initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target The two Phase II datasets from the company’s China partner Hengrui suggest BHB-1893 could be…
Braveheart Bio initiated with a Buy at Stifel
Stifel analyst James Condulis initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $45 price target The firm believes the company’s BHB-1893 is “de-risked” in both obstructive and…
Braveheart Bio initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target Braveheart is a clinical-stage biotechnology company developing BHB-1893 for ob...
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart Bio opens at $30.20, IPO priced at $18 per share
Braveheart Bio (BRVE) – a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases – priced 21.25M sha...
Braveheart Bio indicated to open at $30, IPO priced at $18
Braveheart Bio (BRVE) priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range. Goldman Sachs,…
Braveheart Bio 21.25M share IPO priced at $18.00
The deal size was increased to 21.25M shares of common stock from 18.75M shares of common stock and priced above the $15.00-$17.00 range. Goldman Sachs, Jefferies, TD Cowen, Stifel and…
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart, Attovia join next wave of biotech IPOs
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO
Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Braveheart Bio IPO Registration Document (S-1)
Braveheart Bio has filed to go public with an IPO on the NASDAQ